Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025
Processa Pharmaceuticals reported preliminary Phase 2 data showing its NGC‑Cap regimen increased cancer-killing metabolite exposure and reduced toxic byproducts in metastatic breast cancer patients. The company also enacted a 1-for-25 reverse stock split effective Dec. 16. Shares saw heavy trading following the announcements.
